New Vytorin study not enough of a lift

Has Vytorin been wrongly maligned? A study presented last week appeared to suggest that it had. But Forbes' Matthew Herper looks at the evidence--and talks to the experts--to find that the latest data isn't enough of a shot in the arm. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.